MEDS RSI Chart
Last 7 days
1.4%
Last 30 days
-17.5%
Last 90 days
27.2%
Trailing 12 Months
26.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 9.3M | 8.2M | 8.3M | 8.3M |
2022 | 10.1M | 11.5M | 11.3M | 10.3M |
2021 | 18.0M | 13.3M | 9.5M | 9.9M |
2020 | 8.1M | 12.8M | 16.8M | 17.1M |
2019 | 4.5M | 5.6M | 7.0M | 7.4M |
2018 | 3.1M | 3.2M | 3.3M | 3.8M |
2017 | 2.8M | 2.9M | 3.0M | 3.0M |
2016 | 2.4M | 2.7M | 3.0M | 3.2M |
2015 | 1.9M | 2.8M | 4.1M | 2.1M |
2014 | 1.1M | 1.2M | 1.4M | 1.5M |
2013 | 0 | 0 | 0 | 955.9K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 05, 2024 | patel prashant | acquired | - | - | 150,000 | interim cfo and director |
Jan 05, 2024 | ajjarapu surendra k | acquired | - | - | 150,000 | chairman and ceo |
Jan 16, 2023 | peterson michael l | acquired | - | - | 100,000 | - |
Dec 30, 2022 | newell a. jeffrey | acquired | - | - | 237,186 | - |
Dec 13, 2022 | huffman janet | acquired | - | - | 50,000 | cfo, pao, pfo |
Sep 01, 2022 | pope charles l | acquired | - | - | 54,525 | - |
Sep 01, 2022 | ajjarapu surendra k | acquired | - | - | 51,724 | ceo |
Sep 01, 2022 | patel prashant | acquired | - | - | 8,620 | president and coo |
Sep 01, 2022 | fell donald g. | acquired | - | - | 54,525 | - |
Sep 01, 2022 | huffman janet | acquired | - | - | 21,551 | cfo, pao, pfo |
Which funds bought or sold MEDS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -51.45 | -471 | 10,435 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -78.00 | - | -% |
May 14, 2024 | Qube Research & Technologies Ltd | sold off | -100 | -520 | - | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | new | - | 342,000 | 342,000 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | new | - | 104,427 | 104,427 | -% |
May 13, 2024 | UBS Group AG | new | - | 2,519 | 2,519 | -% |
May 10, 2024 | VANGUARD GROUP INC | new | - | 148,972 | 148,972 | -% |
May 10, 2024 | BlackRock Inc. | new | - | 84,173 | 84,173 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | unchanged | - | 40.00 | 82.00 | -% |
Unveiling Trxade Group Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Trxade Group Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Trxade Group Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | - | - | - | 2,251 | 2,248 | 1,331 | 2,400 | 3,279 | 3,240 | 2,388 | 2,550 | 1,898 | 3,053 | 1,994 | 6,332 | 6,593 | 2,203 | 1,696 | 2,311 | 1,916 | 1,513 | 1,294 |
Gross Profit | -233.7% | -2,278 | 1,705 | 1,645 | 1,557 | 1,578 | 1,372 | 1,171 | 1,336 | 1,240 | 1,281 | 841 | 1,383 | 133 | 1,929 | 2,005 | 1,640 | 1,250 | 1,311 | 1,163 | 1,147 | 847 |
Operating Expenses | 44.4% | 3,681 | 2,550 | 1,990 | 1,904 | 2,422 | 1,591 | 2,274 | 2,304 | 2,023 | 2,577 | 3,411 | 2,028 | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 145.2% | 1,505 | 614 | 305 | 377 | 279 | 230 | 547 | 651 | -116 | 917 | 648 | 448 | 1,713 | 1,783 | 2,540 | 1,452 | 1,239 | 1,133 | 1,031 | 975 | 1,157 |
Interest Expenses | 179.4% | 703 | 252 | 181 | 62.00 | 196 | 130 | 9.00 | 1.00 | 2.00 | 6.00 | 9.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.00 | 13.00 | 16.00 | 18.00 | 18.00 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -231.6% | -11,690 | -3,525 | -1,974 | -677 | -908 | -503 | -1,112 | -965 | -784 | -1,301 | -2,578 | -651 | -2,312 | 138 | -542 | 180 | -495 | 28.00 | 58.00 | 125 | -187 |
Net Income Margin | -169.8% | -2.16* | -0.80* | -0.43* | -0.31* | -0.30* | -0.30* | -0.36* | -0.56* | -0.54* | -0.72* | -0.41* | -0.19* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 37.4% | -386 | -617 | 315 | -945 | 1,216 | -590 | -1,192 | -1,014 | -440 | -752 | -705 | -724 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -42.1% | 12,533 | 21,654 | 3,745 | 4,038 | 3,710 | 4,480 | 5,672 | 5,840 | 5,766 | 5,514 | 6,896 | 9,693 | 9,793 | 11,854 | 11,732 | 11,474 | 5,571 | 5,855 | 5,855 | 3,299 | 2,228 |
Current Assets | -50.4% | 2,753 | 5,548 | 2,095 | 2,386 | 2,093 | 2,373 | 3,347 | 3,597 | 4,374 | 5,189 | 6,536 | 9,155 | 9,221 | 10,643 | 10,123 | 9,795 | 3,803 | 4,315 | 1,952 | 1,491 | 1,466 |
Cash Equivalents | 346.4% | 152 | 34.00 | 746 | 1,194 | 1,095 | 322 | 962 | 1,871 | 3,123 | 3,572 | 4,520 | 5,209 | 5,920 | 6,648 | 4,151 | 7,701 | 2,872 | 3,359 | 540 | 534 | 870 |
Inventory | -100.0% | 968* | 3,027 | 161 | 126 | 66.00 | 76.00 | 127 | 274 | 56.00 | 95.00 | 139 | 470 | 1,258 | 1,647 | 1,819 | 368 | 57.00 | 63.00 | 547 | 62.00 | 80.00 |
Net PPE | -3.8% | 277 | 288 | 60.00 | 62.00 | 65.00 | 68.00 | 71.00 | 74.00 | 99.00 | 13.00 | 15.00 | 161 | 162 | 150 | 151 | 197 | 175 | 11.00 | 13.00 | 14.00 | 15.00 |
Goodwill | -100.0% | - | 5,129 | - | - | - | - | - | - | - | - | - | - | - | 726 | 726 | 726 | 726 | 726 | 726 | 726 | 726 |
Liabilities | 18.8% | 11,991 | 10,094 | 5,040 | 3,383 | 3,367 | 3,333 | 3,868 | 2,953 | 1,996 | 897 | 1,109 | 1,492 | 1,114 | 1,027 | 1,581 | 1,837 | 1,431 | 1,964 | 2,338 | 2,081 | 1,383 |
Current Liabilities | 27.1% | 11,556 | 9,092 | 4,263 | 2,550 | 2,147 | 2,061 | 2,546 | 1,596 | 926 | 655 | 861 | 1,238 | 842 | 535 | 720 | 951 | 521 | 956 | 1,085 | 808 | 860 |
Shareholder's Equity | -95.3% | 542 | 11,560 | - | 655 | 763 | 1,357 | 1,805 | 2,888 | 3,770 | 4,617 | 5,787 | 8,202 | 8,679 | 10,827 | 10,151 | 9,637 | 4,140 | 3,891 | 1,340 | 1,218 | 845 |
Retained Earnings | -54.4% | -33,245 | -21,529 | -21,900 | -19,900 | -19,719 | -18,800 | -18,300 | -17,213 | -16,247 | -15,463 | -14,161 | -11,583 | -10,931 | -8,619 | -8,757 | -8,215 | -8,395 | -7,900 | -7,927 | -7,985 | -8,111 |
Additional Paid-In Capital | 2.1% | 33,788 | 33,090 | 20,586 | 20,560 | 20,483 | 20,193 | 20,112 | 20,083 | 20,018 | 20,080 | 19,948 | 19,785 | 19,611 | 19,446 | 18,909 | 17,852 | 12,536 | 11,790 | 9,268 | 9,204 | 8,956 |
Shares Outstanding | 10.5% | 905 | 819 | 683 | 681 | 626 | 547 | 545 | 545 | 544 | 544 | 541 | 540 | 540 | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | -420 | -42.43 | -16.69 | 18.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 11,457 | - | - | - | 16,922 | - | - | - | 16,922 | - | - | - | 21,541 | - | - | - | 2,653 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 35.9% | -386 | -603 | 329 | -931 | 2,557 | -576 | -1,178 | -1,000 | -426 | -738 | -691 | -710 | -715 | 2,483 | -3,571 | -410 | -182 | 404 | 46.00 | -125 | 42.00 |
Cashflow From Investing | -102.2% | -418 | -207 | -51.80 | 333 | 314 | -55.73 | -280 | 23.00 | - | - | - | - | -14.00 | - | - | -23.50 | -82.25 | - | -40.00 | -210 | - |
Cashflow From Financing | 1496.6% | 1,835 | 115 | -725 | 681 | -28.19 | -7.86 | 550 | -274 | - | -210 | - | - | 1.00 | 13.00 | 22.00 | 5,264 | -222 | 2,415 | - | 166* | 500 |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Revenues | $ 8,272,214 | $ 10,250,168 |
Cost of sales | 5,673,957 | 4,730,897 |
Gross Profit | 2,598,257 | 5,519,271 |
Operating Expenses: | ||
Loss on inventory investment | 875,250 | |
Wage and salary expense | 2,698,178 | 3,581,089 |
Professional fees | 1,466,567 | 466,735 |
Accounting and legal expense | 1,534,377 | 829,751 |
Technology expense | 1,376,908 | 993,185 |
General and administrative | 2,785,633 | 1,689,230 |
Total operating expenses | 9,861,663 | 8,435,240 |
Operating Loss | (7,263,406) | (2,915,969) |
Nonoperating Income (Expense) | ||
Change in fair value of warrant liability | (148,420) | 825,544 |
Interest income | 4,198 | 20,989 |
Goodwill impairment | (5,129,115) | |
Gain on disposal of asset | 2,200 | |
Other income | 14,543 | |
Interest expense | (1,198,346) | (336,206) |
Total nonoperating income (expense) | (6,457,140) | 512,527 |
Net loss from continuing operations | (13,720,546) | (2,403,442) |
Net loss on discontinued operations | (4,123,028) | (1,506,426) |
Net Loss | (17,843,574) | (3,909,868) |
Net loss attributable to TRxADE Health, Inc. | (17,843,574) | (3,472,099) |
Net loss attributable to non-controlling interests | $ (437,769) | |
Net loss per common share from continuing operations | ||
Basic | $ (17.96) | $ (3.48) |
Diluted | (5.76) | (3.47) |
Net loss per common share from discontinued operations | ||
Basic | (5.40) | (2.67) |
Diluted | (1.73) | (2.66) |
Net loss attributable to common stockholders | ||
Basic | (23.35) | (6.15) |
Diluted | $ (7.49) | $ (6.13) |
Weighted average common shares outstanding | ||
Basic | 764,058 | 564,862 |
Diluted | 2,381,443 | 566,609 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets | ||
Cash | $ 151,908 | $ 1,094,894 |
Accounts receivable, net | 821,804 | 629,921 |
Inventory | 968 | 65,523 |
Prepaid assets | 107,774 | 104,461 |
Notes receivable | 1,300,000 | |
Other receivables | 370,608 | |
Current assets of discontinued operations | 198,324 | |
Total Current Assets | 2,753,062 | 2,093,123 |
Property, plant and equipment, net | 277,009 | 65,214 |
Intangible assets and capitalized software, net | 8,962,688 | |
Security deposits | 10,531 | 49,029 |
Operating lease right-of-use assets | 529,623 | 1,051,815 |
Noncurrent assets of discontinued operations | 450,845 | |
Total Assets | 12,532,913 | 3,710,026 |
Current Liabilities | ||
Accounts payable | 2,082,054 | 527,984 |
Accrued liabilities | 400,987 | 271,230 |
Other current liabilities | 70,310 | 67,517 |
Contingent funding liabilities | 1,246,346 | 108,036 |
Lease liabilities – current portion | 139,705 | 196,872 |
Notes payable – current portion | 6,530,000 | 166,667 |
Warrant liability | 736,953 | 588,533 |
Purchase price payable | 350,000 | |
Current liabilities of discontinued operations | 219,952 | |
Total Current liabilities | 11,556,355 | 2,146,791 |
Long Term Liabilities | ||
Lease liabilities – net of current portion | 409,205 | 887,035 |
Notes payable | 25,000 | 333,333 |
Total Liabilities | 11,990,560 | 3,367,159 |
Stockholders’ Equity | ||
Preferred stock value | ||
Common stock, $0.00001 par value; 100,000,000 shares authorized; 905,008, and 626,247 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 9 | 6 |
Additional paid-in capital | 33,788,284 | 20,482,666 |
Retained deficit | (33,245,940) | (19,719,536) |
Total TRxADE Health, Inc stockholders’ equity | 542,353 | 763,136 |
Non-controlling interest in subsidiary | (420,269) | |
Total stockholders’ equity | 542,353 | 342,867 |
Total Liabilities and Stockholders’ Equity | $ 12,532,913 | $ 3,710,026 |
Mr. Surendra K. Ajjarapu | |
trxadehealth.com | |
Pharmaceuticals | |
33 |